Evidence map›Paper›PMID 42666201›Full record

ArticleFrontiers in cellular and infection microbiology2026

Regional surveillance of carbapenem-resistant

Yuyao Hao, Jianhui Li, Junxian Zhang, Shoujun Xie, Mingzhen Zhao, Wei Zhang, Li Xu, Hongtao Ren, Hongmeng Ji, Xueshan Sun and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuyao Hao *Department of Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Jianhui Li *Department of Preventive Medicine, Chengde Medical University, Chengde, Hebei, China.
Junxian ZhangDepartment of Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Shoujun XieDepartment of Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Mingzhen ZhaoHebei Key Laboratory of Panvascular Diseases, Chengde, Hebei, China.
Wei ZhangHebei Key Laboratory of Pathogenic Mechanisms and Diagnosis & Treatment Technologies for Lung Microbiome, Zhangjiakou, Hebei, China.
Li XuDepartment of Clinical Laboratory, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Hongtao RenDepartment of Clinical Laboratory, Xingtai People's Hospital, Xingtai, Hebei, China.
Hongmeng JiDepartment of Clinical Laboratory, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei, China.
Xueshan SunDepartment of Clinical Laboratory, Baoding NO.1 Hospital, Baoding, Hebei, China.
Jidong ZhangDepartment of Clinical Laboratory, People's Hospital of Zunhua City, Zunhua, Tangshan, Hebei, China.
Hongxia ZhangDepartment of Clinical Laboratory, Gucheng County Hospital of Hebei Province, Hengshui, Hebei, China.
Hainan WenDepartment of Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the epidemiological characteristics of CRKP responsible for BSIs in Hebei Province, China. Methods: A total of 100 CRKP isolates were obtained across 15 hospitals in eight cities in Hebei Province, China, between 2022 and 2024. Polymerase chain reaction and short-read whole-genome sequencing were used to characterize the molecular profiles of the strains. Results: All isolates exhibited high-level resistance to β-lactam antibiotics, including a 100% resistance rate to carbapenems and resistance rates of > 97% to β-lactamase inhibitor combinations. The Conclusions: The CRKP isolates from BSIs exhibit significant drug resistance and high virulence characteristics, warranting widespread clinical attention.

Indexed as

BacteremiaCarbapenem-Resistant EnterobacteriaceaeCarbapenemsKlebsiella InfectionsKlebsiella pneumoniaeAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesChinaEpidemiological MonitoringHumansMicrobial Sensitivity TestsPlasmidsVirulenceWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsantimicrobial susceptibilitybloodstream infectioncarbapenem-resistant Klebsiella pneumoniaehypervirulencemolecular epidemiological characteristics

Identifiers

PMID42666201
PMCPMC13521795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.